Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).

被引：1
|
作者：
Marar, Mallika [1 ]
Long Qi [1 ]
Mamtani, Ronac [1 ]
Narayan, Vivek [1 ]
Vapiwala, Neha [1 ]
Parikh, Ravi Bharat [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Use of crowdsourced research to develop a prognostic model for first-line metastatic castrate resistant prostate cancer (mCRPC).
    Zhou, Fang Liz
    Guinney, Justin
    Wang, Tao
    Bare, J. Christopher
    Norman, Thea C.
    Bot, Brian
    Shen, Liji
    Winner, Kimberly Kanigel
    Friend, Stephen Henry
    Abdallah, Kald
    Stolovitzky, Gustavo A.
    Xie, Yang
    Costello, James
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [22] What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
    Davies, Rhian Sian
    Smith, Christian
    Button, Michael Robert
    Tanguay, Jacob
    Barber, Jim
    Palaniappan, Nachiappan
    Staffurth, John
    Lester, Jason Francis
    [J]. ANTICANCER RESEARCH, 2015, 35 (10) : 5615 - 5621
  • [23] Does Pretreatment with Abiraterone Acetate (AA) Or Enzlutamide (ENZA) Affect the Efficacy of Subsequent Cabazitaxel Chemotherapy in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)?
    Body, A.
    Pranavan, G.
    Malik, L.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 56 - 56
  • [24] Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial
    Fizazi, K.
    Delva, R.
    Gravis, G.
    Baciarello, G.
    Theodore, C.
    Gross-Goupil, M.
    Bompas, E.
    Lobbedez, F. Joly
    Tazi, Y.
    L'Haridon, T.
    Hon, T. Nguyen Tan
    Barthelemy, P.
    Culine, S.
    Berdah, J-F.
    Deblock, M.
    Beuzeboc, P.
    Flechon, A.
    Cheneau, C.
    Martineau, G.
    Borget, I.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [25] First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices
    Turpin, Anthony
    Pasquier, David
    Massard, Christophe
    Berdah, Jean-Francois
    Culine, Stephane
    Penel, Nicolas
    [J]. BULLETIN DU CANCER, 2017, 104 (06) : 552 - 558
  • [26] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
    Horgan, Anne M.
    Seruga, Bostjan
    Pond, Greg R.
    Alibhai, Shabbir M.
    Amir, Eitan
    De Wit, Ronald
    Eisenberger, Mario A.
    Tannock, Ian F.
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (02) : 119 - 126
  • [28] Olaparib in metastatic castrate-resistant prostate cancer
    不详
    [J]. BJU INTERNATIONAL, 2020, 126 (02) : 235 - 235
  • [29] Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
    Baciarello, Giulia
    Delva, Remy
    Gravis, Gwenaelle
    Tazi, Youssef
    Theodore, Christine
    Gross-Goupil, Marine
    Bompas, Emmanuelle
    Joly, Florence
    Lharidon, Tifenn
    Thierry Nguyen Tan Hon
    Barthelemy, Philippe
    Culine, Stephane
    Berdah, Jean Francois
    Deblock, Mathilde
    Beuzeboc, Philippe
    Flechon, Aude
    Cheneau, Caroline
    Martineau, Geraldine
    Borget, Isabelle
    Fizazi, Karim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer
    Saad, Fred
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2013, 5 (04) : 201 - 209
12345